"""
Question: 1101 

Evidence: A set of 220 inhibitors belonging to different structure classes and having HIV-1 integrase activity were collected along with their experimental pIC50 values. Analogue based models were generated to predict the pIC50 values for integrase inhibitors using various types of descriptors.

Rationale: The paper compiles existing experimental pIC50 values from the literature and performs in silico docking, MD simulations, and QSAR modeling, including predictions. It does not present new experimental datasets (e.g., sequences, in vitro assays), indicating no previously unpublished experimental data.

Answer: No
"""

"""
Question: 1102 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV). A set of 220 inhibitors were collected from literature along with their experimental pIC50 values.

Rationale: The study focuses on docking to PDB receptor structures and literature-collected inhibitor activities; there is no mention of generating or analyzing HIV nucleotide sequences.

Answer: No
"""

"""
Question: 1103 

Evidence: Computational methods such as Molecular Dynamics (MD), QSAR and molecular docking may help to find highly potent inhibitors out of a pool of compounds. We selected 220 compounds from literature and docked them to 4 HIV-1 integrase inhibitors available in protein data bank (4LH5, 5KRS, 3ZSV, 3ZSQ).

Rationale: The methods are purely computational (docking, MD, QSAR) with no in vitro laboratory evolution or passaging experiments described.

Answer: No
"""

"""
Question: 1104 

Evidence: A set of 220 inhibitors belonging to different structure classes and having HIV-1 integrase activity were collected along with their experimental pIC50 values. Analogue based models were generated to predict the pIC50 values for integrase inhibitors using various types of descriptors.

Rationale: The paper does not report new in vitro susceptibility experiments; it uses literature pIC50 values and predicts activities computationally.

Answer: No
"""

"""
Question: 2101 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV). We selected 220 compounds from literature and docked them to 4 HIV-1 integrase inhibitors available in protein data bank (4LH5, 5KRS, 3ZSV, 3ZSQ).

Rationale: The paper does not report any new HIV sequences, hence no GenBank accessions are provided.

Answer: No
"""

"""
Question: 2102 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV). A set of 220 inhibitors were collected from literature along with their experimental pIC50 values.

Rationale: No new HIV sequences of any type are reported, so there are no GenBank accession numbers for non-laboratory isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV). A set of 220 inhibitors were collected from literature along with their experimental pIC50 values.

Rationale: The paper does not report any GenBank accessions; only PDB IDs for protein structures are mentioned.

Answer: NA
"""

"""
Question: 2202 

Evidence: A set of 220 inhibitors belonging to different structure classes and having HIV-1 integrase activity were collected along with their experimental pIC50 values. In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV).

Rationale: There is no sequencing or mutation listing for individual isolates; the work is computational modeling and docking.

Answer: No
"""

"""
Question: 2301 

Evidence: Analogue and structure based approaches for modelling HIV-1 integrase inhibitors. These ligands were docked against 4 different HIV-1 integrase receptors (PDB IDs: 4LH5, 5KRS, 3ZSQ and 3ZSV).

Rationale: The title and methods explicitly indicate the study concerns HIV-1 integrase.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV). A set of 220 inhibitors were collected from literature along with their experimental pIC50 values.

Rationale: No viral sequences were produced; therefore, no subtypes are reported.

Answer: NA
"""

"""
Question: 2303 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank (PDB IDs 4LH5, 5KRS, 3ZSQ, 3ZSV). We selected 220 compounds from literature and docked them to 4 HIV-1 integrase inhibitors available in protein data bank (4LH5, 5KRS, 3ZSV, 3ZSQ).

Rationale: No sequencing was performed; thus no gene sequencing is reported.

Answer: NA
"""

"""
Question: 2304 

Evidence: We selected 220 compounds from literature and docked them to 4 HIV-1 integrase inhibitors available in protein data bank (4LH5, 5KRS, 3ZSV, 3ZSQ). This study provides a few efficient analogue based models to predict the pIC50 values for various structural classes of HIV-1 integrase inhibitors.

Rationale: The study does not include HIV pol sequence generation or analysis.

Answer: No
"""

"""
Question: 2401 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank.

Rationale: No sequences were reported; geographic origins of sequences are not applicable.

Answer: NA
"""

"""
Question: 2402 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank.

Rationale: No sequencing was done; therefore, there are no sample collection years.

Answer: NA
"""

"""
Question: 2502 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank. Computational methods such as Molecular Dynamics (MD), QSAR and molecular docking may help to find highly potent inhibitors out of a pool of compounds.

Rationale: The paper reports only computational analyses; no sequencing method (including Sanger) was used.

Answer: No
"""

"""
Question: 2503 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank. We performed Molecular Dynamics (MD) simulation to observe the root-mean-square deviation (RMSD).

Rationale: No sequencing was done at all, therefore no NGS was used.

Answer: No
"""

"""
Question: 2504 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank.

Rationale: There were no biological samples or sequencing; thus no cloning prior to sequencing occurred.

Answer: No
"""

"""
Question: 2505 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank. Computational methods such as Molecular Dynamics (MD), QSAR and molecular docking may help to find highly potent inhibitors.

Rationale: No sequencing was performed; hence no single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank. We selected 220 compounds from literature and docked them to 4 HIV-1 integrase inhibitors available in protein data bank.

Rationale: No wet-lab cloning or molecular cloning of viral genomes was described.

Answer: No
"""

"""
Question: 2601 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank.

Rationale: No plasma HIV sequencing was performed or reported.

Answer: No
"""

"""
Question: 2602 

Evidence: In our study molecular docking was carried out on 4 different receptors that were downloaded from the protein data bank. Computational methods such as Molecular Dynamics (MD), QSAR and molecular docking may help to find highly potent inhibitors.

Rationale: No PBMC HIV sequencing was performed or reported.

Answer: No
"""

"""
Question: 2603 

Evidence: The study provides computational docking, MD simulations and QSAR modeling and uses literature pIC50 values. No sequencing of plasma virus is described anywhere in the methods or results.

Rationale: Because plasma sequencing was not performed, there is no count of such samples.

Answer: NA
"""

"""
Question: 2604 

Evidence: The paper does not describe any sequencing of HIV from PBMCs and focuses on in silico analyses. Receptors were downloaded from the protein data bank.

Rationale: Since PBMC sequencing was not done, the number of such samples is not reported.

Answer: NA
"""

"""
Question: 2605 

Evidence: No human sample collection or sequencing is reported. The work centers on docking inhibitors to PDB HIV-1 integrase structures and QSAR predictions.

Rationale: Without sequences from individuals, one cannot determine whether sequences came from active replication.

Answer: NA
"""

"""
Question: 2606 

Evidence: No sequencing of HIV genomes is described in the study. Computational docking and MD use PDB structures, not patient-derived proviral DNA.

Rationale: Without sequencing, there is no basis to attribute sequences to the proviral reservoir.

Answer: NA
"""

"""
Question: 2701 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. No clinical cohorts, patient enrollment, or sample collection are described.

Rationale: There are no samples or individuals reported; thus no infant/child sampling.

Answer: No
"""

"""
Question: 2702 

Evidence: The study is entirely computational (docking, MD, QSAR) and does not involve human participants or clinical sampling. No clinical trial enrollment is mentioned.

Rationale: Without individuals in the study, none were in a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: No individuals were studied; the work is based on literature compounds and PDB structures. There is no mention of clinical enrollment or trials.

Rationale: Because there are no individuals, they cannot all be in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: The paper does not report collection or sequencing of HIV from individuals. It focuses on computational modeling of inhibitorâ€“integrase interactions.

Rationale: No individuals had samples obtained for sequencing; the number is not applicable.

Answer: NA
"""

"""
Question: 3102 

Evidence: There is no HIV sequencing in the paper. The analyses are docking, MD simulations and QSAR predictions using literature data.

Rationale: Since no individuals were sequenced, the question is not applicable.

Answer: NA
"""

"""
Question: 4101 

Evidence: No HIV sequences from individuals are reported. The study uses PDB structures and literature pIC50 values.

Rationale: Without sequences, there is no reporting of ART-naive sequences.

Answer: No
"""

"""
Question: 4102 

Evidence: The paper contains no patient-derived HIV sequences. Methods and results are confined to computational analyses.

Rationale: Without sequences, there is no reporting of sequences from ARV-experienced individuals.

Answer: No
"""

"""
Question: 4103 

Evidence: No sequencing of HIV from any individuals is described. The work centers on docking to PDB integrase structures and QSAR.

Rationale: Since no sequences are reported at all, neither ART-naive nor ART-experienced sequences are included.

Answer: No
"""

"""
Question: 4104 

Evidence: The study reports no sequencing. There are no samples from ART-naive individuals.

Rationale: With no sequencing, counts of ART-naive sample sequences cannot be given.

Answer: NA
"""

"""
Question: 4105 

Evidence: No individuals or clinical data are described. The dataset consists of inhibitors and computational modeling.

Rationale: Without human subjects, ART histories are not applicable.

Answer: No
"""

"""
Question: 4201 

Evidence: There is no epidemiological analysis or sequencing in the paper. The focus is on computational modeling of integrase inhibitors.

Rationale: Prevalence of transmitted drug resistance requires sequence data; none are provided.

Answer: No
"""

"""
Question: 4202 

Evidence: No patient-derived sequences or cohorts are reported. The study is computational (docking, MD, QSAR).

Rationale: Pretreatment drug resistance prevalence is not addressed.

Answer: No
"""

"""
Question: 4301 

Evidence: The paper does not involve patient treatment data. It mentions approved integrase inhibitors in background but no individual treatments.

Rationale: Without individuals, no drug classes were received by participants.

Answer: NA
"""

"""
Question: 4302 

Evidence: Currently there are three FDA approved integrase inhibitors available in the market namely Raltegravir, Elvitegravir and Dolutegravir. The study, however, does not include clinical subjects or treatment records.

Rationale: The paper does not report information on individuals receiving integrase inhibitors.

Answer: No
"""

"""
Question: 4303 

Evidence: The paper has no clinical cohort or treatment data. It focuses on computational docking and QSAR.

Rationale: Therefore, it does not report information on individuals who received protease inhibitors.

Answer: No
"""

"""
Question: 4304 

Evidence: No individuals or ART regimens are part of the study. The data are literature inhibitors and PDB structures.

Rationale: With no individuals, regimen uniformity cannot be addressed.

Answer: NA
"""

"""
Question: 4305 

Evidence: The study has no participants or ART histories. It is an in silico modeling study.

Rationale: INSTI-naivety of individuals is not applicable.

Answer: NA
"""

"""
Question: 4403 

Evidence: There are no individuals or ART regimens in this computational study. No clinical data are presented.

Rationale: Counts of individuals with more than one regimen are not applicable.

Answer: NA
"""

"""
Question: 4404 

Evidence: No clinical participants or ART histories are included. The paper centers on docking, MD, and QSAR.

Rationale: Not applicable to count individuals with more than two regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: No individuals are included in the study. Therefore, the number of ART regimens per individual is not discussed.

Rationale: Not applicable.

Answer: NA
"""

"""
Question: 4406 

Evidence: There are no individuals in the study. The paper does not report any ART regimens.

Rationale: Not applicable.

Answer: NA
"""

"""
Question: 4501 

Evidence: Currently there are three FDA approved integrase inhibitors available in the market namely Raltegravir, Elvitegravir and Dolutegravir. The paper does not include any patient treatment data.

Rationale: Without individuals, the number who received dolutegravir is not applicable.

Answer: NA
"""

"""
Question: 4502 

Evidence: The paper contains no clinical treatment data. It focuses on computational modeling and literature-derived inhibitor activity values.

Rationale: The number of individuals who received darunavir is not applicable.

Answer: NA
"""

"""
Question: 5101 

Evidence: No HIV sequencing data are reported in the paper. The analyses are docking, MD simulation, and QSAR modeling.

Rationale: Without sequences, drug resistance mutation counts in individuals cannot be reported.

Answer: NA
"""

"""
Question: 5102 

Evidence: The study does not report any HIV sequences or genotyping of individuals. It is purely computational with literature activity values.

Rationale: Therefore, no INSTI resistance mutations in individuals are reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: No sequencing or mutation analysis is reported. The paper does not include patient data.

Rationale: TDF resistance mutations are not addressed.

Answer: NA
"""

"""
Question: 5104 

Evidence: The paper does not report any individual-level mutation development. It focuses on docking and QSAR without sequencing.

Rationale: No INSTI-resistance mutations are reported to have developed in individuals.

Answer: NA
"""

"""
Question: 6101 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. Analogue based models were generated to predict the pIC50 values for integrase inhibitors.

Rationale: The paper does not perform phenotypic susceptibility testing; it relies on literature values and predictions.

Answer: NA
"""

"""
Question: 6102 

Evidence: A set of 220 inhibitors were collected from literature along with their experimental pIC50 values. We designed a few inhibitors on the basis of the structure activity relationship and predicted their pIC50 values by using generated analogue/ligand-based models.

Rationale: The study does not generate new experimental IC values; predicted pIC50s are not novel in vitro measurements.

Answer: No
"""

"""
Question: 6103 

Evidence: The paper reports no new phenotypic susceptibility experiments. It uses literature pIC50 values and computational predictions.

Rationale: No novel fold-change IC50 data are presented.

Answer: No
"""

"""
Question: 6104 

Evidence: The study does not describe performing any phenotypic assays. It focuses on docking, MD, and QSAR.

Rationale: Since no assay was used, there is nothing to report.

Answer: NA
"""

"""
Question: 6105 

Evidence: The paper includes docking, MD, and QSAR analyses but no cell-based replication measurements. No replication capacity data are described.

Rationale: Replication capacity was not measured or reported.

Answer: No
"""

"""
Question: 6106 

Evidence: No phenotypic susceptibility testing was performed in this study. The paper only references literature pIC50 values and computational predictions.

Rationale: Without a phenotypic assay, no drugs were tested phenotypically within this study.

Answer: NA
"""

"""
Question: 7101 

Evidence: The study did not generate viral isolates. It performed docking of small molecules to PDB HIV-1 integrase structures and MD/QSAR.

Rationale: No site-directed mutant viral isolates are described.

Answer: No
"""

"""
Question: 7102 

Evidence: The paper reports no in vitro passage experiments. It is a computational study using docking, MD, and QSAR.

Rationale: Therefore, none of the isolates result from in vitro passage.

Answer: No
"""